In our study, we searched for prognostic biomarkers of treatment response to IFNβ among pro- and anti-inflammatory cytokines in the serum and CSF of RR-MS patients who were prospectively followed up for a considerable time period (mean 5.3 years). This evidence concerns the gene IFNB1 and myeloid sarcoma.